In reference to email dated April 24, 2025 regarding clarification for significant increase in the volume of security across exchanges, in the recent past, GlaxoSmithKline Pharmaceuticals has clarified that the Company has made all the necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time and has not withheld any material information/ event that in our opinion would have a bearing on the operations/ performance of the Company which include all price sensitive information, etc. The significant increase in the volume of the Company is purely market driven. They reiterated that the Company will continue to comply with the listing regulations requirements and keep the Stock Exchange informed of all price sensitive information as and when they arise.
The above information is a part of company’s filings submitted to BSE.
